Relcovaptan (SR-49059) is a non-peptide vasopressin receptor antagonist, selective for the V1a subtype.

[1] It has shown positive initial results for the treatment of Raynaud's disease and dysmenorrhoea, and as a tocolytic,[2] although it is not yet approved for clinical use.

This hormonal preparation article is a stub.

You can help Wikipedia by expanding it.